We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





Researchers Testing Do-It-Yourself COVID-19 Vaccine on Themselves

By HospiMedica International staff writers
Posted on 04 Aug 2020
A group of researchers have formed the Rapid Deployment Vaccine Collaborative (RaDVaC), developed their own do-it-yourself COVID-19 vaccine and begun testing the vaccine on themselves.

RaDVaC members come from a range of backgrounds and professions, but most of them are trained scientists and engineers. More...
This expanding core group met through their associations with Harvard Medical School and HMS Professor George Church. The project was launched in the Boston area but is expanding steadily across the US and throughout the world.

RaDVaC’s mission is rapid development, testing, and public sharing of vaccine recipes that are simple enough to be produced and administered by individual citizen scientists and qualified healthcare professionals. The group of researchers has drawn on decades of scientific literature describing proven vaccine designs to develop, produce, and self-administer an intranasally delivered vaccine. RaDVaC members have designed, produced, and self-administered several progressive generations of nasal vaccines against SARS-CoV-2. Currently, over 20 of them have self-administered the vaccine which is made up of fragments (peptides) of the virus, similar to the ones already being used for hepatitis B and human papillomavirus.

The group has not filed any patents or other intellectual property protections, and all information on their vaccine designs, material procurement, production, self-administration, and testing are freely shared on their website. In addition to publicly releasing the results of our vaccine work, RaDVaC is working with other researchers to advance new kinds of testing to assess immunity. The group aims to motivate others around the world to build on their efforts, to share their research openly, and to deploy protective vaccines rapidly and safely.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Pediatric Cast Saw
CSP-201 Quietcast
New
Needle Guide Disposable Kit
Verza
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: the deep tissue in vivo sound printing (DISP) platform, which combines ultrasound with low-temperature–sensitive liposomes loaded with crosslinking agents (Photo courtesy of Elham Davoodi and Wei Gao/Caltech)

New Ultrasound-Guided 3D Printing Technique to Help Fabricate Medical Implants

3D bioprinting technologies hold considerable promise for advancing modern medicine by enabling the production of customized implants, intricate medical devices, and engineered tissues designed to meet... Read more

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.